Publications by authors named "Elliot Ehrich"

Claim this Profile
O
Opioid system modulation with buprenorphine/samidorphan combination for major depressive disorder: two randomized controlled studies.
Maurizio Fava, Michael E Thase, Madhukar H Trivedi, Elliot Ehrich, William F Martin

Mol Psychiatry· July 2020

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitigation of Olanzapine-Induced Weight Gain With Samidorphan, an Opioid Antagonist: A Randomized Double-Blind Phase 2 Study in Patients With Schizophrenia.
William F Martin, Christoph U Correll, Peter J Weiden, Ying Jiang, Sanjeev Pathak, Elliot W Ehrich

Am J Psychiatry· June 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Endogenous opioid system dysregulation in depression: implications for new therapeutic approaches.
Marta Peciña, Jordan F Karp, Sanjay Mathew, Mark S Todtenkopf, Elliot W Ehrich

Mol Psychiatry· April 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abuse Potential of Buprenorphine/Samidorphan Combination Compared to Buprenorphine and Placebo: A Phase 1 Randomized Controlled Trial.
Sanjeev Pathak, Bradley Vince, Debra Kelsh, Megan J Shram, Beatrice Setnik, Elliot Ehrich

J Clin Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Abuse Potential of Samidorphan: A Phase I, Oxycodone-, Pentazocine-, Naltrexone-, and Placebo-Controlled Study.
Sanjeev Pathak, Bradley Vince, Debra Kelsh, Beatrice Setnik, Narinder Nangia, Elliot Ehrich

J Clin Pharmacol· February 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effects of the Opioid System Modulator, Samidorphan, on Measures of Alcohol Consumption and Patient-Reported Outcomes in Adults with Alcohol Dependence.
Stephanie S O'Malley, Mark S Todtenkopf, Yangchun Du, Elliot Ehrich, Bernard L Silverman

Alcohol Clin Exp Res· October 2018

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of aripiprazole lauroxil in schizophrenic patients presenting with severe psychotic symptoms during an acute exacerbation.
Steven G Potkin, Robert Risinger, Yangchun Du, Jacqueline Zummo, Anjana Bose, Elliot Ehrich

Schizophr Res· December 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of Aripiprazole Lauroxil on Metabolic and Endocrine Profiles and Related Safety Considerations Among Patients With Acute Schizophrenia.
Henry A Nasrallah, John W Newcomer, Robert Risinger, Yangchun Du, Jacqueline Zummo, Elliot W Ehrich

J Clin Psychiatry· November 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
O
Opioid Modulation With Buprenorphine/Samidorphan as Adjunctive Treatment for Inadequate Response to Antidepressants: A Randomized Double-Blind Placebo-Controlled Trial.
Maurizio Fava, Asli Memisoglu, Michael E Thase, J Alexander Bodkin, Madhukar H Trivedi, Elliot Ehrich

Am J Psychiatry· May 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Effect of aripiprazole lauroxil on agitation and hostility in patients with schizophrenia.
Leslie Citrome, Yangchun Du, Robert Risinger, Srdjan Stankovic, Amy Claxton, Elliot W Ehrich

Int Clin Psychopharmacol· March 2016

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A randomized, double-blind, placebo-controlled trial of aripiprazole lauroxil in acute exacerbation of schizophrenia.
Herbert Y Meltzer, Robert Risinger, Henry A Nasrallah, Yangchun Du, Jacqueline Zummo, Elliot W Ehrich

J Clin Psychiatry· August 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
U
Use of Remifentanil in a Novel Clinical Paradigm to Characterize Onset and Duration of Opioid Blockade by Samidorphan, a Potent μ-Receptor Antagonist.
Megan J Shram, Bernard Silverman, Elliot Ehrich, Edward M Sellers, Ryan Turncliff

J Clin Psychopharmacol· June 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Evaluation of opioid modulation in major depressive disorder.
Elliot Ehrich, Ryan Turncliff, Yangchun Du, Richard Leigh-Pemberton, Emilio Fernandez

Neuropsychopharmacology· May 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics of samidorphan, a novel opioid antagonist, in healthy volunteers.
Ryan Turncliff, Lauren DiPetrillo, Bernard Silverman, Elliot Ehrich

Clin Ther· February 2015

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia.
Ryan Turncliff, Marjie Hard, Yangchun Du, Robert Risinger, Elliot W Ehrich

Schizophr Res· November 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A placebo-controlled pilot study of the novel opioid receptor antagonist ALKS-33 in binge eating disorder.
Susan L McElroy, Anna I Guerdjikova, Thomas J Blom, Scott J Crow, Asli Memisoglu, Elliot W Ehrich

Int J Eat Disord· April 2013

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Single- and multiple-dose pharmacokinetics of long-acting injectable naltrexone.
Joi L Dunbar, Ryan Z Turncliff, Qunming Dong, Bernard L Silverman, Elliot W Ehrich

Alcohol Clin Exp Res· March 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Pharmacokinetics of long-acting naltrexone in subjects with mild to moderate hepatic impairment.
Ryan Z Turncliff, Joi L Dunbar, Qunming Dong, Bernard L Silverman, Elliot W Ehrich

J Clin Pharmacol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and tolerability of long-acting injectable naltrexone for alcohol dependence: a randomized controlled trial.
James C Garbutt, Henry R Kranzler, Stephanie S O'Malley, David R Gastfriend, Helen M Pettinati, Elliot W Ehrich

JAMA· April 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A pilot evaluation of the safety and tolerability of repeat dose administration of long-acting injectable naltrexone (Vivitrex) in patients with alcohol dependence.
Bankole A Johnson, Nassima Ait-Daoud, Henri-Jean Aubin, Wim Van Den Brink, Richard Guzzetta, Elliot Ehrich

Alcohol Clin Exp Res· September 2004

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Dose-effect relationships of nonsteroidal anti-inflammatory drugs: a literature review.
Paul Emery, Sheldon X Kong, Elliot W Ehrich, Douglas J Watson, Tanveer E Towheed

Clin Ther· August 2002

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis